Whitney & Co’s Aimmune Therapeutics AIMT Stock Holding History

Whitney & Co’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-48	Closed	-$1K	–	522
2018 Q3	$1K	Buy	+48	New	+$1.36K	﹤0.01%	527

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Whitney & Co's AIMT Position: Q4 2018 in Review

Whitney & Co sold out of Aimmune Therapeutics (AIMT) in Q4 2018, closing a stake of 48 shares — an estimated $1K sold.

Whitney & Co first reported a position in AIMT in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 132 funds tracked by Wall St. Rank hold AIMT as of Q4 2018.

Whitney & Co reported no remaining Aimmune Therapeutics position as of Q4 2018 after selling out during the quarter.
Whitney & Co sold 48 Aimmune Therapeutics shares in Q4 2018, an estimated $1K.
Whitney & Co first reported a position in Aimmune Therapeutics in Q3 2018 and held it in 1 quarter.
Whitney & Co's Aimmune Therapeutics position peaked at $1K in Q3 2018.
132 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2018.

Based on Whitney & Co's 13F filing for Q4 2018, filed 7 Feb 2019.